Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q1 Loss Rises on Opko Deal Charge


RXi Pharmaceuticals this week reported its first-quarter financial results, posting a sharply increased net loss on a one-time charge associated with its purchase of the RNAi drug assets of Opko Health in early March.

For the three-month period ended March 31, RXi’s net loss was $14.4 million, compared with $1.9 million in the same quarter a year earlier. Driving the loss was a $12.3 million charge related to the fair value of RXi common shares issued to Opko under the companies’ deal (GSN 3/7/2013).

RXi’s revenues were $100,000, versus no revenues in the year-ago period, and reflect money received under government grants.

Research and development spending surged to $13.8 million from $1.2 million, primarily due to the charge associated with the Opko deal, while general and administrative expenses fell $100,000 to $700,000.

At the end of the first quarter, RXi had cash and cash equivalents totaling $19.6 million.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.